MIA SH3 domain containing

Gene Context Sentence

Table 2. Analysis of context sentence of MIA gene in 5 abstracts.

PMID Gene Context Sentence
32380209 Isolate I0305/19 and other GI-19 viruses isolated in China have the amino acid sequence MIA at positions 110-112 in the S protein.
32420954 Anosmia and dysgeusia have been reported as particular symptoms.4,5 Notably, these sensory symptoms seem to have a peculiar trend, such as usually precede the onset of respiratory symp- toms. […] Anos- mia and dysgeusia frequently preceded respiratory complaints. […] Anosmia and dysgeusia seem to be short-lived and self-resolving in COVID-19, thus a neurotoxic effect swiftly disappearing and/or cytopathic damage could be hypothesized similarly to other viral infections.
32443177 In order to follow biosafety recommendations, we used Ultrasound-Guided Minimally Invasive Autopsy (MIA-US) to assess the systemic involvement of COVID-19 and present the results of ten initial autopsies. […] We used MIA-US for tissue sampling of lungs, liver, heart, kidneys, spleen, brain, skin, skeletal muscle and testis for histology and RT-PCR to detect SARS-COV-2-RNA. […] MIA-US is safe and effective for the study of severe COVID-19.
32505774 IgM/IgG and total antibodies against SARS-CoV-2 were measured by a cyclic enhanced fluorescence assay (CEFA) and a microsphere immunoassay (MIA), respectively. […] Independent performance evaluation included imprecision, reproducibility, specificity and cross-reactivity (CEFA n = 320, MIA n = 364). […] Agreement of CEFA and MIA was 90.4%-94.5% (Kappa: 0.81-0.89) in 302 samples. […] CEFA and MIA detected SARS-CoV-2 antibodies in 26.2% and 26.3%, respectively, of ED patients. […] Longitudinal antibody kinetic changes by CEFA and MIA measurements correlated well and exhibited three types of seroconversion. […] Rigorously validated CEFA and MIA assays are reliable for detecting antibodies to SARS-CoV-2 and show promising clinical utility when evaluating immune response in hospitalized and convalescent patients, but are not useful for early screening at patient’s initial ED visit.
33175911 Minimally invasive autopsy (MIA) is a validated and safe method to establish the cause of death (COD), mainly in low-resource settings. […] However, the additional clinical value of MIA in Coronavirus disease (COVID-19) patients in a high-resource setting is unknown. […] The objective was to assess if and how MIA changed clinical COD and contributing diagnoses in deceased COVID-19 patients. […] MIA consisted of whole-body CT and CT-guided Tru-Cut® biopsies. […] MIA COD and contributing diagnoses were established during a multi-disciplinary meeting. […] The main outcomes were alterations in CCOD and contributing diagnoses after MIA, and the contribution of each diagnostic modality. […] MIA led to an alteration in 15/18 (83%) patients. […] MIA found a new COD (1/5), a more specific COD (1/5), a less certain COD (1/5), or a contributing diagnosis to be the COD (2/5). […] MIA, especially histological examination, can add valuable new clinical information regarding the cause of death in COVID-19 patients, even in a high-resource setting with wide access to premortem diagnostic modalities. […] MIA may provide important clinical insights and should be applied in the current ongoing pandemic.